Sage Therapeutics, Inc.
SAGE
$6.67
-$0.084-1.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -354.40M | -400.67M | -337.59M | -445.67M | -503.14M |
| Total Depreciation and Amortization | 807.00K | 1.03M | 1.31M | 1.39M | 1.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.37M | 47.68M | 58.41M | 70.04M | 62.19M |
| Change in Net Operating Assets | 1.13M | 84.76M | -42.28M | 589.00K | 14.82M |
| Cash from Operations | -311.09M | -267.19M | -320.15M | -373.65M | -424.74M |
| Capital Expenditure | -- | -- | 112.00K | -216.00K | -328.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 173.03M | 266.68M | 262.05M | 341.72M | 387.81M |
| Cash from Investing | 173.03M | 266.68M | 262.17M | 341.50M | 387.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.87M | 11.18M | 11.18M | 12.52M | 5.19M |
| Repurchase of Common Stock | -496.00K | -404.00K | -664.00K | -269.00K | -276.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -117.00K | -117.00K | -117.00K | -117.00K | -- |
| Cash from Financing | 9.25M | 10.66M | 10.40M | 12.14M | 4.91M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.81M | 10.15M | -47.59M | -20.02M | -32.34M |